drugset / Trial / NCT07362992

Topical Tranexamic Acid to Reduce Blood Loss During Cesarean Delivery

NCT07362992

RandomizedParallel-groupOpen-labelPrevention

Summary

The goal of this clinical trial is to learn whether applying topical tranexamic acid (TXA) directly to the uterine incision during cesarean delivery can reduce surgical bleeding compared to placebo. The study will include pregnant women aged 18-51 undergoing elective cesarean delivery at term (37 weeks or more). The main questions it aims to answer are: * Does topical TXA shorten uterine closure time? * Does topical TXA reduce the need for additional hemostatic sutures? Researchers will compare women receiving topical TXA to those receiving placebo (normal saline) to see if TXA reduces intraoperative bleeding and improves surgical outcomes. Participants will: * Be randomly assigned to receive either topical TXA or placebo during cesarean delivery. * Have standard surgery and postoperative care identical in both groups. * Provide routine clinical data, including hemoglobin levels and recovery outcomes, from their medical records.

Timeline

Start
2026-07-01
Primary completion
2028-12-01
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 500 mg Topical

Indications

No indication recorded.